Technology Assessment: Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy, Part 4. Thalidomide for Multiple Myeloma. Figure 9

You Are Here: AHRQ Archive Home > Technology Assessment Archive > Report on the Relative Efficacy of Oral Cancer Therapy for Medicare Beneficiaries Versus Currently Covered Therapy

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Figure 9: Reporting of Paraprotein Responses Across Studies

Overall Response (=25%)^a=x%
m protein reduction:

100%=x%
≥90%^a=x%
≥75%^a=x%
≥50%^a=x%
≥25-49%^a=x%

^a. To accommodate the various ways of presenting response rates found in this literature, we have considered the Overall Response to capture responses from 25 to 100%. Sub-categories generally represent 90-99%, 75-89%, 50-74%, and 25-49%—or more inclusive if the paper was presented in that manner.

Return to Document

The information on this page is archived and provided for reference purposes only.